Background: Since the emergence of coronavirus disease 2019 (COVID-19), the impact of the disease on various organs, including the liver, has been a subject of investigation. Reports have shown liver dysfunction in COVID-19 patients, and its association with severity and mortality remains of interest. Aim:To evaluate the prevalence of liver dysfunction and its correlation with severity and mortality in patients with COVID-19 infection. Methods: This cross-sectional observational study was conducted between June 2021 and December 2022 in a hospital setting. Patients diagnosed with moderate to severe COVID-19 were included and categorized into two groups based on disease severity. Data of liver function tests, viral markers, inflammatory markers, and patient mortality were recorded at regular intervals during hospitalization and post-discharge. Results: A total of 500 COVID-19 patients, with a mean age of 46.12 years were included in the study.Sixty four percent of patients had severe COVID-19 infection, while 36% had moderate infection.Liver dysfunction were significantly higher in patients with severe COVID-19 infection compared to those with moderate infection(p<0.001).The moderate COVID-19 group had 80.34% of survivors (143/178) whereas, the severe COVID-19 group had 21.74% of survivors (70/322).Serum bilirubin, direct bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and prothrombin time-international normalized ratio (PT-INR) exhibited a significant correlation with the inflammatory markers C-reactive protein (CRP) and ferritin (p≤0.001 for each). Conclusion:The present study indicates a higher prevalence of liver dysfunction among patients with COVID-19, especially among those with severe infection. Patients with liver dysfunction might hold higher odds of severity and mortality of COVID-19 infection.